Skip to main content
Haemato AG logo

Haemato AG — Investor Relations & Filings

Ticker · HAEK ISIN · DE000A289VV1 LEI · 529900Q3CGRYVCW7E340 F Wholesale and retail trade
Open in API
Filings indexed 188 across all filing types
Latest filing 2022-01-14 Earnings Release
Country DE Germany
Listing F HAEK

About Haemato AG

https://haemato.de/en/start.html

Haemato AG is a pharmaceutical company focused on the specialty pharma market, concentrating on treatments for chronic diseases and high-priced therapies. The company's business activities include the development, acquisition, licensing, and distribution of a product portfolio that comprises innovative patent-protected medicines, biosimilars, and generics. The portfolio also extends to narcotics, including cannabis products, as well as over-the-counter (OTC) products and special cosmetics. Haemato AG's primary therapeutic areas of focus are HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology.

Recent filings

Filing Released Lang Actions
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
Earnings Release Classification · 99% confidence The document is titled 'News Details' and begins with a date and a headline about distributing PCR devices. It explicitly states it is a 'DGAP-Media' release and ends with 'End of Media Release' and information about DGAP distribution services. This format strongly indicates a press release or general corporate news announcement that does not fit the specific financial report categories (like 10-K, IR, ER). Since it is a general announcement disseminated via a regulatory service (DGAP), and it doesn't fit other specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements. FY 2022
2022-01-14 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
Annual Report Classification · 95% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for HAEMATO AG for the fiscal year 2020. It contains detailed balance sheets (Aktiva/Passiva), notes (Anhang), and breakdowns of assets, liabilities, and equity. While it is not a full 10-K (which is a US-specific filing), it functions as the primary annual financial report for a German entity. Given the provided categories, '10-K' is the standard classification for a comprehensive annual financial report, even for non-US entities in this taxonomy. FY 2020
2022-01-06 German
HAEMATO AG reports figures for the 3rd quarter of 2021: Further increase in revenue and earnings as well as confirmation of revenue and earnings expectations for 2021
Earnings Release Classification · 100% confidence The document explicitly reports on the financial figures for the '3rd quarter of 2021' and the 'first nine months of 2021'. It details revenue, EBIT, and equity changes for this interim period. Key phrases like 'reports figures for the 3rd quarter of 2021' and the inclusion of nine-month data strongly indicate a comprehensive report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it contains detailed financial metrics and analysis, suggesting it is more comprehensive than just the initial highlights. It is also not a full Annual Report (10-K) as it covers only nine months. 9M 2021
2021-11-18 English
HAEMATO: HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
M&A Activity Classification · 99% confidence The document is titled 'News Details' and is explicitly identified as a 'DGAP-Media' release, dated 25 October 2021. It announces a strategic business development: HAEMATO seeking marketing authorization and planning distribution for a botulinum toxin product under an exclusive license and supply agreement with Huons BioPharma. This type of announcement, detailing strategic partnerships, product pipeline updates, and market expansion plans, is characteristic of a general corporate news release or regulatory filing that doesn't fit the highly specific categories like 10-K, ER, or DIV. Since it is a general announcement disseminated via a service like DGAP, and it is not a formal report (like 10-K or IR) nor a specific transaction report (like DIRS or POS), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2021-10-25 English
HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
Regulatory Filings Classification · 99% confidence The document is an 'Ad-hoc' announcement dated October 25, 2021, disclosing inside information according to Article 17 MAR (Market Abuse Regulation). It details a strategic agreement between HAEMATO and Huons BioPharma regarding the distribution and marketing authorization of a botulinum toxin product in Europe. This type of announcement, which communicates material, non-public information about business operations, regulatory plans, or strategic alliances, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER) or specific corporate actions (like DIV, SHA, DIRS). Since it is a general regulatory disclosure concerning business strategy and regulatory steps, the most appropriate fallback category is 'Regulatory Filings' (RNS), which covers miscellaneous regulatory announcements that don't fit elsewhere.
2021-10-25 English
Half-yearly financial statements 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT 2021' and contains comprehensive financial statements, including a consolidated profit and loss account, balance sheet, cash flow statement, and management discussion for the period 01.01.2021 to 30.06.2021. It provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-10-07 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.